NICE Add us as a preferred source on Google

X @nicecomms

🔄 Data last refreshed 1 month ago

🤝

Make a deal with NICE

👋 Unclaimed listing — auto-generated from public data; rates are estimates, not set by the creator. 🔒 Paid proposals held safely in escrow — released only when the work's approved.

This is an unclaimed, auto-generated listing. It was built only from NICE’s publicly available X information. NICE has not claimed, verified, or endorsed it, and is not affiliated with, sponsored by, or a partner of SocialDB — no partnership or endorsement is implied, and any prices shown are estimates, not set by the creator.

✓ Is this you? Claim it 🗑 Remove this listing

Followers

236.3K

Posts

17.3K

Following

1.1K

Account age

17 yrs

💰 Suggested sponsorship rate

🎁 Free analysisfor NICE

🕵️Fake Followers CheckReal-audience % & bot risk→ 📊Engagement rateBenchmarked vs. peers→ 💰What they chargeFair sponsored-post price→

Known for

NICE has completed the first test of a new approach to keeping guidance aligned and up-to-date.

Using evidence from our updated type 2 diabetes guideline, we've updated recommendations for 4 medicines through our whole lifecycle approach programme: https://t.co/lLoMOFThbM

4.9K views NICE has completed the first test of a new approach to keeping guidance aligned and up-to-date. Using evidence from our updated type 2 diabetes guideline, we've updated recommendations for 4 medicines through our whole lifecycle approach programme: https://t.co/lLoMOFThbM

📢Suspected sepsis guideline updated

We now recommend clinicians consider procalcitonin testing for some people with suspected severe sepsis to support assessment and decision-making.

Find out more: https://t.co/HjJVGf0wrT

3.4K views 📢Suspected sepsis guideline updated We now recommend clinicians consider procalcitonin testing for some people with suspected severe sepsis to support assessment and decision-making. Find out more: https://t.co/HjJVGf0wrT

More than 1,760 people with newly diagnosed multiple myeloma could benefit from a new NICE-recommended treatment option.

Evidence shows it can help people live longer and keep the disease under control for longer than standard treatment:
https://t.co/EWxuk4PU35

3K views More than 1,760 people with newly diagnosed multiple myeloma could benefit from a new NICE-recommended treatment option. Evidence shows it can help people live longer and keep the disease under control for longer than standard treatment: https://t.co/EWxuk4PU35

More than 390 patients with advanced womb cancer could benefit from a new treatment option.

Durvalumab can be used with chemotherapy and then continued to help keep advanced or recurrent womb cancer under control.

Learn more: https://t.co/cTpROQKi5s

2.8K views More than 390 patients with advanced womb cancer could benefit from a new treatment option. Durvalumab can be used with chemotherapy and then continued to help keep advanced or recurrent womb cancer under control. Learn more: https://t.co/cTpROQKi5s

📊 Post performance

📊 Activity & format

Posting cadence

7.4 / week

Posts daily — consistently active for a campaign window.

Content mix

Mostly images

Recent: 6 video · 8 image · 3 text.

Follower / following

217×

Follows 1.1K back. A strong ratio — an audience that follows them, not a follow-for-follow network.

Recent posts

View on X ↗

🔥 Top post NICE has completed the first test of a new approach to keeping guidance aligned and up-to-date. Using evidence from our updated type 2 diabetes guideline, we've updated recommendations for 4 medicines through our whole lifecycle approach programme: https://t.co/lLoMOFThbM 4.9K❤ 16🔁 5

An NHS treatment option is now available for people with rare desmoid tumours. NICE has recommended nirogacestat, the first targeted treatment we’ve recommended for this non-cancerous condition. Find out more: https://t.co/m4h6Mk4sao 1.6K❤ 1

▶ A new treatment option for untreated mantle cell lymphoma could help some people live longer and delay disease progression. NICE final guidance recommends ibrutinib with R-CHOP as an alternative to stem cell transplant: https://t.co/RUKyp… 1.9K❤ 4

📢Suspected sepsis guideline updated We now recommend clinicians consider procalcitonin testing for some people with suspected severe sepsis to support assessment and decision-making. Find out more: https://t.co/HjJVGf0wrT 3.4K❤ 8🔁 4

▶ Hundreds more donated organs could become available for transplant each year. Listen to our latest #NICEtalks podcast to learn how machine perfusion technology is changing transplantation and why NICE has recommended routine NHS access: h… 1.6K❤ 6 📣Getting your HealthTech evidence right first time is crucial. Join our NICE Advice workshop to understand how NICE committees evaluate healthtech, experience a mock committee exercise and strengthen your evidence strategy for market acce… 3.1K

Strong evidence alone does not guarantee NHS adoption. Our system engagement service helps life sciences companies spot adoption barriers before they become roadblocks. Read how: https://t.co/5C5lIVTjDB #LifeSciences #MarketAccess 2.7K❤ 2

Jimi was one of the first people to receive CRISPR gene therapy, a treatment that NICE recommended for use on the NHS in England in 2025. Read Jimi's story: https://t.co/0uMh5hRg64 #SickleCellAwarenessMonth #SickleCellMonth 2.1K❤ 4🔁 1

Many people with OCD and BDD live with symptoms for years before receiving the right support. Draft NICE guidance aims to help healthcare professionals identify these conditions earlier and offer more personalised care. Share your views:… 1.9K NICE recommends Enhertu for people with HER2-low advanced breast cancer. Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. Learn more: 4.6K❤ 7🔁 6

▶ Around 200 children and young people with rare nerve tumours are set to benefit after we published final guidance recommending a new treatment today. Mirdametinib is an option for some families when surgery isn't possible. Find out mor… 2.1K❤ 3🔁 1

▶ 🎙️ Hundreds more donated organs could become available for transplant each year. Listen to our latest #NICEtalks podcast to learn how machine perfusion technology is changing organ transplantation and why NICE has recommended routine NHS … 1.8K

💡 Facts

🗓️Joined X in 2009 — 17 years ago.

👁️Averages 2.7K views per post.

📤Posts about 7.4× per week.

💬0% engagement rate.

🏅Earned the 100K Followers for passing 100K followers.

🕵️ Fake follower check

Estimated

37/100

Low Credibility score

66%

Mixed Real audience

Medium Fake-follower risk

High Data confidence

Est. 66% real, active audience · Medium fake-follower risk.
Low engagement (~1.1% of followers engage each post) — a sign of an inflated or inactive audience.
Organic base — far more followers than accounts it follows.
Established account (17+ years old).
0% engagement — below the ~2.2% typical for this size.

Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.

About

Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.

📸 Gallery

🔀 Audience overlap

Estimated

Estimated shared audience with similar creators — useful for avoiding overlap (or doubling down) when planning a campaign.

HSE Ireland 18%

WHO African Region 18%

The Globe and Mail 16%

National Rail 12%

India in UAE 11%

International Labour Organization 11%

More like this

International Labour Organization

@ilo

226.2K Followers

Frequently asked questions

How much does NICE charge for a sponsorship?

NICE hasn't published fixed prices yet. Send a proposal through SocialDB and agree terms directly — your payment is held in escrow until the work is approved.

How do I contact NICE for a brand deal or collaboration?

Send a paid deal or collab request right here on SocialDB — we notify NICE, and once they accept, your payment is held safely in escrow and released when the work is approved. You don't need to track down an email.

How many followers does NICE have?

NICE has 236,347 followers on X.